Cantor Fitzgerald Weighs in on PRQR FY2025 Earnings

ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for ProQR Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim forecasts that the biopharmaceutical company will post earnings of ($0.36) per share for the year. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.31) per share.

Several other research firms have also commented on PRQR. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Raymond James raised ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their price target for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. Oppenheimer started coverage on ProQR Therapeutics in a research report on Friday, January 10th. They issued an "outperform" rating and a $15.00 price target for the company. JMP Securities restated a "market outperform" rating and set a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, ProQR Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.

ProQR Therapeutics Stock Performance

NASDAQ PRQR traded down $0.00 on Wednesday, reaching $2.23. 333,333 shares of the stock traded hands, compared to its average volume of 344,407. The company has a market cap of $181.82 million, a price-to-earnings ratio of -6.96 and a beta of 0.30. ProQR Therapeutics has a 12 month low of $1.61 and a 12 month high of $4.62. The company has a fifty day moving average price of $3.06 and a 200-day moving average price of $2.55.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. The firm had revenue of $4.22 million during the quarter, compared to analysts' expectations of $4.75 million. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%.

Hedge Funds Weigh In On ProQR Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Ballentine Partners LLC acquired a new position in shares of ProQR Therapeutics in the fourth quarter valued at approximately $61,000. OneDigital Investment Advisors LLC lifted its holdings in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after buying an additional 15,550 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock worth $107,000 after buying an additional 7,300 shares in the last quarter. Finally, Privium Fund Management B.V. lifted its holdings in ProQR Therapeutics by 0.9% during the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company's stock worth $10,251,000 after buying an additional 51,663 shares in the last quarter. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).